Brenda L. Palucki
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Biochemical Analysis and Sensing Techniques, Regulation of Appetite and Obesity, Adipokines, Inflammation, and Metabolic Diseases, melanin and skin pigmentation, Asymmetric Synthesis and Catalysis
Most-Cited Works
- → Design and Pharmacology of N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a Potent, Selective, Melanocortin Subtype-4 Receptor Agonist(2002)190 cited
- → Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist(2004)42 cited
- → Metabolic Activation of a 1,3-Disubstituted Piperazine Derivative: Evidence for a Novel Ring Contraction to an Imidazoline(2005)39 cited
- → Discovery and activity of (1R,4S,6R)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-2-methyl-2-azabicyclo[2.2.2]octane-6-carboxamide (3, RY764), a potent and selective melanocortin subtype-4 receptor agonist(2005)37 cited
- → Spiro(indoline-3,4′-piperidine) growth hormone secretagogues as ghrelin mimetics(2001)36 cited
- → Determination of brain and plasma drug concentrations by liquid chromatography/tandem mass spectrometry(2000)32 cited
- → 2-Piperazinecarboxamides as potent and selective melanocortin subtype-4 receptor agonists(2005)22 cited
- → Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist(2011)16 cited
- Synthesis of heterocyclic compounds via intramolecular [4+2] cycloadditions of conjugated enynes(1997)
- → Discovery of (2S)‐N‐[(1R)‐2‐[4‐cyclohexyl‐4‐[ [(1,1‐dimethylethyl)‐amino]carbonyl]‐1‐piperidinyl]‐1‐ [(4‐fluorophenyl)methyl]‐2‐oxoethyl]‐4‐methyl‐2‐piperazinecarboxamide (MB243) (I), a Potent and Selective Melanocortin Subtype‐4 Receptor Agonist.(2005)